Xuanzhu Biopharmaceutical Co., Ltd. (2575)

Overview

Xuanzhu Biopharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies. Founded in 2017 and headquartered in Shanghai, China, the company focuses on addressing unmet medical needs in therapeutic areas including digestive diseases, oncology, and non-alcoholic steatohepatitis (NASH). With a robust pipeline featuring over ten drug assets actively under development, Xuanzhu engages in discovering and advancing novel pharmaceuticals designed to improve patient outcomes. The company’s work contributes significantly to advancements in treatments for gastrointestinal disorders, various cancers, and liver conditions associated with NASH. Its emphasis on targeted drug candidates and precise mechanisms of action distinguishes Xuanzhu within the global biopharmaceutical landscape, as it successfully progresses drug candidates from preclinical stages through clinical trials.

Products and Services

• Therapies for Digestive Diseases

  Xuanzhu specializes in developing innovative therapies specifically targeting digestive diseases. These treatments aim to provide relief and improve quality of life for patients suffering from various gastrointestinal disorders.

• Oncology Drug Candidates

  Focusing on cancer treatment, Xuanzhu's oncology drug candidates are engineered to tackle several types of cancer. The company prioritizes the development of novel therapeutics that can offer better efficacy and safety profiles compared to current treatment options.

• Treatments for Non-Alcoholic Steatohepatitis (NASH)

  Recognizing the increasing prevalence of NASH, Xuanzhu actively works on developing therapies aimed at this liver condition. The company’s efforts are directed towards providing solutions that can help manage and potentially reverse the effects of NASH on liver health.

• Clinical Research and Development

  Xuanzhu is engaged in rigorous clinical research and development processes, enhancing its drug pipeline through scientific innovation. This includes conducting preclinical studies and clinical trials that evaluate the safety and effectiveness of its drug candidates.

• Global Collaboration Initiatives

  To foster innovation further, Xuanzhu collaborates with global partners in the biopharmaceutical industry. These partnerships drive shared knowledge and resources, enhancing the potential advancement of new therapies to address various medical needs.